http://www.reportbuyer.com/rss.htmlLearn more about Branding in the Pharma & Healthcare industry. Reports provide information on Mega Brands, Optimization and the Launch phase.en-gbReportbuyerservice@reportbuyer.comenquiries@redwiredesign.comhttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/branding/using_public_relations_launch_grow_extend_brands.htmlSavvier consumers and competition from generic drugs have made commercial success, whether at market entry or during brand maturity, more elusive. at the same time, new technologies have greatly expanded the ability of cost-efficient Public Relations to support pharmaceutical brand growth. Thus, while industry trends introduce challenges to product commercialization, technology is enabling PR leaders to fashion innovative PR campaigns. def2f949bc5ae93db21faa7cb8b94263Tue, 03 Mar 2009 12:00:00 GBSales & Marketing/Brandinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/branding/medical_science_liaisons.htmlStudy Overview as companies compete for the attention of physicians, key opinion leaders (KOLs) and thought leaders, they increasingly use medical science liaisons (MSLs) to build and strengthen KOL relationships. as laws continue to restrict relationships between pharmaceutical companies and physicians, finding the right way to build and maintain relationships can have a dramatic impact on company success. This research uncovers the optimal size, mix and service frequencies of these elite medical specialist groups in an effort to build strong, productive relationships. f3b7ba0b3a78b3b2fb801f6684fbc38aMon, 02 Feb 2009 12:00:00 GBSales & Marketing/Brandinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/branding/driving_successful_pharma_brands_1.htmlEnsure brand sales success - make the right investment choices at the right time : Would you like to take the guesswork out of spending on brand commercialization efforts? Are you sure when and how much to invest in brand promotional activities, market research, reimbursement efforts and medical affairs initiatives? Driving Successful Pharma Brands addresses these questions - and more - to give you the information you need to avoid costly mistakes and propel brands' bottom-line success. Our study contains real-world budgets for 13 US brands, representing a variety of brand sizes, therapeutic areas and drug classes. Understanding these resource allocations in terms of both raw dollars and real-world contexts creates a powerful advantage for brand teams, marketing units, market research personnel, reimbursement groups and other parties involved in every brand's life. 94454b4bf79fe8462752e182b74ecf45Thu, 01 Jan 2009 12:00:00 GBSales & Marketing/Brandinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/branding/public_relations_excellence.htmlStudy Snapshot Savvy bio-pharma marketers have long used Public Relations to support their brands. However, field research suggests few companies have utilized the full potential of PR Campaigns across the entire product lifecycle - Preparing, Launching, Growing & Extending the Brand. New technologies and market changes have greatly expanded the reach and potential of cost-efficient PR through web sites, online social networks, blogs, and traditional media sources. 07f71caf2fe0ef51999d31a51b32dd4bFri, 10 Oct 2008 12:00:00 GBSales & Marketing/Brandinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/branding/pharmaceutical_new_product_commercialization.htmlLong and costly product development cycles make it essential for pharmaceutical companies to maximize limited staff and resources to the development of compounds with the greatest potential market value. From the time a company's R&D (Research and Development) group begins to develop a new prescription medicine until it receives FDA approval to market the drug in the United States, a drug company typically spends $1 billion over the course of 10 to 15 years. Leading companies are integrating commercial insights earlier and earlier into the new product process in an effort to identify and target promising compounds, reduce development cycle time, focus resources for greatest impact and increase their potential for launching a blockbuster drug. df8407a783a06d3f4676b084c8575a8fMon, 07 Jul 2008 12:00:00 GBSales & Marketing/Brandinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/branding/guidebook_pharma_brand_optimization.htmlWith pipelines diminishing and generics becoming more aggressive, pharmaceutical companies must maximize their brands' value and time on the market. Strategic and well-orchestrated lifecycle management efforts are crucial to maintaining a brand's long-term health. Cutting Edge Information's report A Guidebook to Pharma Brand Optimization analyzes the inner-workings of lifecycle management strategy, development and implementation processes. 469c947d0e42abb5bbd9f4c78126df15Tue, 01 Jan 2008 12:00:00 GBSales & Marketing/Brandinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/branding/delivering_maximum_brand_impact_via_pharmaceutical_market_analytics.htmlMarket analytics functions play a key role in helping pharmaceutical and biotechnology companies make informed decisions, avoid risk, and uncover opportunities for growth. Although market analytics insights can be vital to corporate success, the function's full value often remains unrealized. This research examines how to maximize the business value of analytics through optimal structuring, staffing and positioning of analytics activities. e0d9070430437f6887e0bf32f8d97d3bSat, 07 Jul 2007 12:00:00 GBSales & Marketing/Brandinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/branding/small_specialty_drug_branding.html Commercializing new drugs continues to challenge companies across the pharmaceutical and biotechnology sectors. Cutting Edge Information published this study to assist individuals and product teams who seek guidance in the allocation of pre- and post-launch marketing resources for small and specialty brands. The information contained in this report is based on primary research gathered from brand managers and directors, marketing executives and marketing support function team members working with brands marketed in the United States, Europe and worldwide. 897b430c4251120d9796fd05093d5247Mon, 01 May 2006 12:00:00 GBSales & Marketing/Brandinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/branding/marketing_mid_tier_pharmaceutical_brands.html The following recommendations and conclusions were among Cutting Edge Information's top study findings: Mid-level drugs thrive in underserved markets and, therefore, must prepare for inevitable competition and generic entrants Some of the most successful mid-level brands have branded themselves in markets where few competitors exist or have done poor jobs of commercializing their drugs. While pharmaceutical and biotechnology companies can capitalize on the opportunities these markets present, this situation leave many mid-level brands vulnerable to competitive threats, especially generic drugs. With relatively low resource to draw upon, mid-level drugs are susceptible to losing their market share rapidly, even prior to patent expiration. 89018f535352ab3d020c6f041e7b13c3Mon, 01 May 2006 12:00:00 GBSales & Marketing/Brandinghttp://www.reportbuyer.com/pharma_healthcare/sales_marketing/branding/launching_pharmaceutical_megabrands.htmlLaunching Pharmaceutical Megabrands: Best Practices in Marketing Blockbusters (SM-124) profiles an elite group of high performing pharmaceutical companies that have demonstrated effective operating practices and winning strategies in the area of Marketing Pharmaceutical Blockbusters. By studying other organizations' successful approaches to marketing blockbusters, your company can improve its multi-phased pre-launch marketing support to drive rapid uptake of new products. After reading this report, you will know how world-class pharmaceutical companies drive commercially focused drug development to create blockbuster megabrands. 16a3c77e05ac9c18ddac572ebc65719aSun, 01 Feb 2004 12:00:00 GBSales & Marketing/Branding